Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable ( MSS) colorectal cancer (CRC)

被引：0
|
作者：
Christenson, Eric S.
Wala, Jeremiah A.
Parkinson, Rose
Collins, Natalie B.
Jakubowski, Christopher
Lin, Jea-Ren
Wang, Hao
Ho, Won Jin
Chan, Sabrina
Klein, Rachel
Cetasaan, Yvette
Johnson, Emma
Berg, Maureen
Meyerhardt, Jeffrey
Schlechter, Benjamin
Singh, Harshabad
Sorger, Peter K.
Giannakis, Marios
Azad, Nilofer
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT007
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation
    van der Pol, Ymke
    Yilma, Binyam
    Morris, Van K.
    Chao, Calvin
    Harris, Michelle
    Guinney, Justin
    Kopetz, Scott
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy A Phase 1 Nonrandomized Clinical Trial
    Fakih, Marwan
    Sandhu, Jaideep
    Lim, Dean
    Li, Xiaochen
    Li, Sierra
    Wang, Chongkai
    JAMA ONCOLOGY, 2023, 9 (05) : 627 - 634
  • [23] Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results
    Saeed, Anwaar
    Park, Robin
    Dai, Junqiang
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Saeed, Azhar
    Collins, Zachary
    Thompson, Kayra
    Barbosa, Lori
    Mulvaney, Kelly
    Manirad, Vanna
    Phadnis, Milind
    Williamson, Stephen K.
    Baranda, Joaquina Celebre
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).
    Hubbard, Joleen Marie
    Patel, Manish R.
    Bekaii-Saab, Tanios S.
    Falchook, Gerald Steven
    Freilich, Bradley L.
    Dasari, Arvind
    Knisely, Benjamin T.
    Anderson, Marlisa
    Chiang, Gary Gene
    Webster, Kevin R.
    Sperry, Sam
    Barton, Jeremy
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Coexistence of Microsatellite Stable (MSS) and Instable Colorectal Cancer (CRC) Primary Colon Cancers: A Case Report and Brief Review of Literature
    Wassimi, S.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 : S78 - S78
  • [26] A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractoryRAS-mutated microsatellite stable (MSS) colorectal cancer
    Johnson, Benny
    Haymaker, Cara
    Morris, Van K.
    Dasari, Arvind
    Higbie, Victoria Serpas
    Shen, John Paul
    Parseghian, Christine
    Morelli, Maria Pia
    Huey, Ryan
    Lee, Michael S.
    Willis, Jason
    Raghav, Kanwal P.
    Yuan, Ying
    Zebala, John
    DePinho, Ronald A.
    Kopetz, Scott
    Overman, Michael
    CANCER RESEARCH, 2023, 83 (08)
  • [27] Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
    Telli, Tugba Akin
    Bregni, Giacomo
    Vanhooren, Michele
    Conde, Rita Saude
    Hendlisz, Alain
    Sclafani, Francesco
    CANCER TREATMENT REVIEWS, 2022, 110
  • [28] Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC)
    Lentz, Robert William
    Blatchford, Patrick Jud
    Hu, Junxiao
    Pitts, Todd
    van Bokhoven, Adrie
    Robinson, Hannah Ruth
    Balmaceda, Nicole Baranda
    Toegel, Emily Baiyee
    Leal, Alexis Diane
    Kim, Sunnie S.
    Davis, S. Lindsey
    Lieu, Christopher Hanyoung
    Wadlow, Raymond Couric
    Spencer, Kristen Renee
    Scott, Aaron J.
    Boland, Patrick M.
    Hochster, Howard S.
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naive, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
    Christenson, Eric
    Mahadevan, Daruka
    Kazmi, Syed Mohammad Ali
    Manda, Sudhir
    Sohal, Davendra
    Hutson, Thomas E.
    Fu, Siqing
    Martz, Ashley
    Kordahi, Stephanie
    Barbu, Emilia Alina
    Flies, Dallas
    Langermann, Solomon
    Chisamore, Michael Jon
    Gutierrez, Martin
    Matrana, Marc Ryan
    Spira, Alex
    Wadlow, Raymond Couric
    Guha, Udayan
    Myint, Han
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC)
    Gadea, O. Saavedra Santa
    Greil, R.
    De Jonge, M. J. A.
    Tan, D.
    Jerusalem, G.
    Damian, S.
    Grell, P.
    Wainberg, Z.
    Wolf, J.
    Joerger, M.
    Carlino, M. S.
    Kasper, S.
    Yap, T. A.
    Otero, J.
    Yang, X.
    Nesbitt, V.
    Kim, J.
    Lee, L. Ho
    Choudhury, S.
    Leal, T. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S552 - S553
12345